A venture-backed biotechnology company has raised $2.5 million to initiate clinical trials of a novel point-of-care technology for detecting pathogens instantly.
FREMONT, CA: Hememics Biotechnologies has secured $2.5 million, led by a consortium of high net worth Vietnamese investors, AMVI Partners. This round of funding would be used to support U.S. Food and Drug Administration (FDA) submission by furthering more clinical trials of a novel point-of-care technology for detecting pathogens in under a minute. Hememics Biotechnologies empowers hospitals to rapidly identify infectious disease pathogens within seconds instead of days at a fraction of the cost. The company offers a significant advantage in post-incubation blood testing, which detects the type of bacteria immediately in blood samples, eliminating the costly and time-consuming steps to identify the proper antibiotic.
Producing a handheld device and a multiplex panel chip that can be used anywhere for ultra-rapid detection of bacteria,.Hememics Biotechnologies is thrilled to engage in this productive partnership with Vietnamese investors through AMVI Partners, Hememics' technology is addressing the growing need for rapid diagnostics in the discovery of sexually transmitted infections.
Hememics Biotechnologies is a biotech organization, developing rapid diagnostic test platforms. The company empowers hospitals to rapidly identify infectious disease pathogens within seconds instead of days at a fraction of the cost. Hememics provides a vital advantage in post-incubation blood testing that detects the kind of bacteria in blood samples, reducing the costly and time-consuming steps to recognize the proper antibiotic. Hememics' patented HEMSOL™ solution preserves antibodies conjugated with carbon nanotubes on the chip. Hememics proprietary platform liberates diagnostic testing from the central lab, making it possible and affordable to conduct tests at the bedside or in the field for almost instant answers.
